P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model

Frontiers in Pharmacology

Volumn 4 NOV, Issue , 2013, Pages

  Adkins, Chris E ^a   Mittapalli, Rajendar K ^a   Manda, Vamshi K ^a   Nounou, Mohamed I ^a   Mohammad, Afroz S ^a   Terrell, Tori B ^a   Bohn, Kaci A ^a   Yasemin, Celik ^b   Grothe, Tiffany R ^b   Lockman, Julie A ^b   Lockman, Paul R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b WEST TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Autoradiography; Chemotherapy; Drug resistance; Fluorescence microscopy; Tumor

Indexed keywords

CARBON 14; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BLOOD TUMOR BARRIER; BRAIN METASTASIS; BRAIN TISSUE; BREAST CANCER; CANCER CELL; CANCER MODEL; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION;

EID: 84889637940     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00136     Document Type: Article

References (53)

1. Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25. doi: 10.1016/j.nbd.2009.07.030
2. Agarwal, S., Hartz, A. M., Elmquist, W. F., and Bauer, B. (2011). Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr. Pharm. Des. 17, 2793-2802. doi: 10.2174/138161211797440186
3. Agarwal, S., Manchanda, P., Vogelbaum, M. A., Ohlfest, J. R., and Elmquist, W. F. (2013). Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab. Dispos. 41, 33-39. doi: 10.1124/dmd.112.048322
4. Baumert, C., and Hilgeroth, A. (2009). Recent advances in the development of P-gp inhibitors. Anticancer Agents Med. Chem. 9, 415-436. doi: 10.2174/1871520610909040415
5. Begley, D. J. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48, 136-146. doi: 10.1111/j.2042-7158.1996.tb07112.x
6. Breedveld, P., Beijnen, J. H., and Schellens, J. H. (2006). Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27, 17-24. doi: 10.1016/j.tips.2005.11.009
7. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., et al. (2005). The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577-2582. doi: 10.1158/0008-5472.CAN-04-2416
8. Choi, J. S., and Li, X. (2005). The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24, 95-100. doi: 10.1016/j.ejps.2004.10.002
9. Chopra, A. (2004). "11C-Labeled rhodamine-123," in Molecular Imaging and Contrast Agent Database (MICAD) (Bethesda:National Center for Biotechnology Information).
10. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287. doi: 10.1177/38.9.1974900
11. Dagenais, C., Rousselle, C., Pollack, G. M., and Scherrmann, J. M. (2000). Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20, 381-386. doi: 10.1097/00004647-200002000-00020
12. Deeken, J. F., and Loscher, W. (2007). The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13, 1663-1674. doi: 10.1158/1078-0432.CCR-06-2854
13. Demeule, M., Shedid, D., Beaulieu, E., Del Maestro, R. F., Moghrabi, A., Ghosn, P. B., et al. (2001). Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int. J. Cancer 93, 62-66. doi: 10.1002/ijc.1306
14. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665-15670. doi: 10.1073/pnas.95.26.15665
15. Forster, S., Thumser, A. E., Hood, S. R., and Plant, N. (2012). Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS ONE 7:e33253. doi: 10.1371/journal.pone.0033253
16. Gallo, J. M., Li, S., Guo, P., Reed, K., and Ma, J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 63, 5114-5117.
17. Guo, Z., Zhu, J., Zhao, L., Luo, Q., and Jin, X. (2010). Expression and clinical significance of multidrug resistance proteins in brain tumors. J. Exp. Clin. Cancer Res. 29, 122. doi: 10.1186/1756-9966-29-122
18. Hagenbuch, B., and Meier, P. J. (2004). Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447, 653-665. doi: 10.1007/s00424-003-1168-y
19. Hawkins, B. T., and Davis, T. P. (2005). The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173-185. doi: 10.1124/pr.57.2.4
20. Hegmann, E. J., Bauer, H. C., and Kerbel, R. S. (1992). Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52, 6969-6975.
21. Henson, J. W., Cordon-Cardo, C., and Posner, J. B. (1992). P-glycoprotein expression in brain tumors. J. Neurooncol. 14, 37-43. doi: 10.1007/BF00170943
22. Hoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T., Ohtsuki, S., and Terasaki, T. (2013). Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci.102, 3343-3355. doi: 10.1002/jps.23575
23. Iusuf, D., Teunissen, S. F., Wagenaar, E., Rosing, H., Beijnen, J. H., and Schinkel, A. H. (2011). P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J. Pharmacol. Exp. Ther. 337, 710-717. doi: 10.1124/jpet.110.178301
24. Jouan, E., Le Vee, M., Denizot, C., Da Violante, G., and Fardel, O. (2012). The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Fundam. Clin. Pharmacol. doi: 10.1111/j.1472-8206.2012.01071.x [Epub ahead of print].
25. Kemper, E. M., Verheij, M., Boogerd, W., Beijnen, J. H., and van Tellingen, O. (2004). Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur. J. Cancer 40, 1269-1274. doi: 10.1016/j.ejca.2004.01.024
26. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26. doi: 10.1016/S0169-409X(00)00129-0
27. Lockman, P. R., Koziara, J. M., Mumper, R. J., and Allen, D. D. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12, 635-641. doi: 10.1080/10611860400015936
28. Lockman, P. R., Koziara, J., Roder, K. E., Paulson, J., Abbruscato, T. J., Mumper, R. J.,et al. (2003a). In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20, 705-713. doi: 10.1023/A:1023492015851
29. Lockman, P. R., Mumper, R. J., and Allen, D. D. (2003b). Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method. J. Neurochem. 86, 627-634. doi: 10.1046/j.1471-4159.2003.01888.x
30. Lockman, P. R., McAfee, G., Geldenhuys, W. J., Van der Schyf, C. J., Abbruscato, T. J., and Allen, D. D. (2005a). Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J. Pharmacol. Exp. Ther. 314, 636-642. doi: 10.1124/jpet.105.085381
31. Lockman, P. R., Van der Schyf, C. J., Abbruscato, T. J., and Allen, D. D. (2005b). Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J. Neurochem. 94, 37-44. doi: 10.1111/j.1471-4159.2005.03162.x
32. Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., et al. (2010). Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664-5678. doi: 10.1158/1078-0432.CCR-10-1564
33. Lockman, P. R., Roder, K. E., and Allen, D. D. (2001). Inhibition of the rat blood-brain barrier choline transporter by manganese chloride. J. Neurochem. 79, 588-594. doi: 10.1046/j.1471-4159.2001.00589.x
34. Loscher, W., and Potschka, H. (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76, 22-76. doi: 10.1016/j.pneurobio.2005.04.006
35. Mittapalli, R. K., Manda, V. K., Bohn, K. A., Adkins, C. E., and Lockman, P. R. (2013). Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier. J. Neurosci. Methods 219, 188-195. doi: 10.1016/j.jneumeth.2013.07.001
36. Mittapalli, R. K., Vaidhyanathan, S., Sane, R., and Elmquist, W. F. (2012). Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342, 33-40. doi: 10.1124/jpet.112.192195
37. Munic, V., Hlevnjak, M., and Erakovic Haber, V. (2011). Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur. J. Pharm. Sci. 43, 359-369. doi: 10.1016/j.ejps.2011.05.003
38. Pardridge, W. M. (2007). Blood-brain barrier delivery. Drug Discov. Today, 12, 54-61. doi: 10.1016/j.drudis.2006.10.013
39. Poller, B., Iusuf, D., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., and Schinkel, A. H. (2011). Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab. Dispos. 39, 729-735. doi: 10.1124/dmd.110.037317
40. Polli, J. W., Olson, K. L., Chism, J. P., John-Williams, L. S., Yeager, R. L., Woodard, S. M., et al. (2009). An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos. 37, 439-442. doi: 10.1124/dmd.108.024646
41. Schinkel, A. H., Wagenaar, E., Mol, C. A., and van Deemter, L. (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97, 2517-2524. doi: 10.1172/JCI118699
42. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., and Borst, P. (1995). Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96, 1698-1705. doi: 10.1172/JCI118214
43. Smith, Q. R., and Allen, D. D., (2003). In situ brain perfusion technique. Methods Mol. Med. 89, 209-218.
44. Smith, Q. R., and Takasato, Y. (1986). Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann. N. Y. Acad. Sci. 481, 186-201. doi: 10.1111/j.1749-6632.1986.tb27150.x
45. Summerfield, S. G., Read, K., Begley, D. J., Obradovic, T., Hidalgo, I. J., Coggon, S., et al. (2007). Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322, 205-213. doi: 10.1124/jpet.107.121525
46. Takasato, Y., Rapoport, S. I., and Smith, Q. R. (1984). An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247,(Pt 2), H484-H493.
47. Taskar, K. S., Rudraraju, V., Mittapalli, R. K., Samala, R., Thorsheim, H. R., Lockman, J., et al. (2012). Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29, 770-781. doi: 10.1007/s11095-011-0601-8
48. Tengvar, C., Hultstrom, D., and Olsson, Y. (1983). An improved Percoll density gradient for measurements of experimental brain edema. Addition of sucrose to an isotonic gradient in an attempt to balance osmotic conditions during density determinations. Acta Neuropathol. 61, 201-206. doi: 10.1007/BF00691986
49. Tews, D. S., Nissen, A., Külgen, C., and Gaumann, A. K. (2000). Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J. Neurooncol. 50, 227-237. doi: 10.1023/A:1006491405010
50. Toth, K., Vaughan, M. M., Peress, N. S., Slocum, H. K., and Rustum, Y. M. (1996). MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149, 853-858.
51. Wadhwani, K. C., Caspers-Velu, L. E., Murphy, V. A., Smith, Q. R., Kador, P. F., and Rapoport, S. I. (1989). Prevention of nerve edema and increased blood-nerve barrier permeability-surface area product in galactosemic rats by aldose reductase or thromboxane synthetase inhibitors. Diabetes 38, 1469-1477. doi: 10.2337/diab.38.11.1469
52. Wang, F., Zhou, F., Kruh, G. D., and Gallo, J. M. (2010). Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 12, 1043-1049. doi: 10.1093/neuonc/noq056
53. Wang, Q., Yang, H., Miller, D. W., and Elmquist, W. F. (1995). Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem. Biophys. Res. Commun. 211, 719-726. doi: 10.1006/bbrc.1995.1872